Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
RSV, Merck
Novel Monoclonal Antibody Protects Infants Against RSV
Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and for infants and children under the age of 2 years at increased risk for severe disease and entering their second RSV season. It is administered as a single, 105-mg intramuscular dose.
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory syncytial virus (RSV)-associated infections in infants.
Merck antibody reduces RSV-related disease, hospitalizations in trial
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.
FierceBiotech
1d
With trial win, Merck's RSV antibody clesrovimab looks poised to take on Sanofi and AZ's Beyfortus
Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.
Business Wire
1d
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease …
Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...
pharmaphorum
1d
MSD preparing to take on Beyfortus with RSV antibody
In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...
Pharmabiz
3h
Merck presents positive results from phase 2b/3 trial of clesrovimab, an investigational RSV preventative monoclonal antibody at IDWeek 2024
Clesrovimab (MK-1654) is an investigational, extended half-life monoclonal
antibody
(mAb) developed as a passive immunization for the prevention of
RSV
. Clesrovimab is designed to be administered ...
Daily
12h
The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.
The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.
STAT
1d
Potential competition for RSV prophylactic Beyfortus
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
2d
WA could be better protected against RSV this winter. Here’s why
Respiratory virus season is underway, but Washington is more prepared than it was last year to protect against some severe ...
7d
RSV, Flu and COVID-19 season is here, so do you need three vaccines?
COVID-19, influenza and RSV are the main threats between October and May. There are vaccines for all three viruses, so you ...
1d
on MSN
Merck's RSV antibody for infants effective in reducing some types of infections in study (Oct 17)
(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...
cidrap.umn
4d
Study: Resistance to antibody rare in RSV breakthrough cases
A new study in The Lancet Infectious Diseases describes the genotypic and phenotypic characteristics of respiratory syncytial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Revised Standard Version
Human respiratory syncytial virus
Feedback